Exploration of Extravascular Tissue and Synovial Fluid Distribution of Extended Half-Life Factor IX Concentrates by Physiologically Based Pharmacokinetic Modelling
Clinical Pharmacokinetics · 15.11.2026
DOI: 10.1007/s40262-026-01716-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacokinetics, online erschienen am 15.11.2026. Verfasst von Sjoerd F Koopman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Pharmacy-Clinical Pharmacology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: SYMPHONY NWO-NWA consortium.
Abstract (Originalsprache)
BACKGROUND: Extended half-life factor IX (EHL-FIX) concentrates are a mainstay of prophylactic treatment in haemophilia B due to their prolonged plasma half-life and less frequent administration. Plasma FIX activity levels do not necessarily correlate with haemostatic efficacy, possibly due to its extravascular tissue distribution while still contributing to haemostasis. Importantly, tissue-specific exposure of EHL-FIX concentrates remains insufficiently characterised. OBJECTIVES: We aimed to characterise and compare FIX distribution across plasma, extravascular and synovial tissue using physiologically based pharmacokinetic (PBPK) modelling. METHODS: PBPK models were developed in PK-Sim®/MoBi® to simulate plasma concentration-time profiles following a 50 IU/kg dose of eftrenonacog alfa (rFIX-Fc), albutrepenonacog alfa (rIX-FP) and nonacog beta pegol (N9-GP). The models incorporated binding affinity (Kd) to collagen type IV (Col4), the neonatal Fc receptor (FcRn) and a vascular endothelial binding partner. A synovium module was implemented to estimate joint-specific exposure. RESULTS: Predicted extravascular distribution profiles differed markedly among EHL-FIX concentrates. rFIX-Fc demonstrated the greatest extravascular distribution, followed by rIX-FP, whereas N9-GP showed minimal distribution. For rFIX-Fc and rIX-FP, highest exposure was predicted in the spleen, lung and kidney. KdFcRn was higher for rFIX-Fc than rIX-FP, while KdCol4 was comparable. No KdCol4 for N9-GP was identified. Synovial fluid concentration predictions indicated highest exposure for rFIX-Fc, modest exposure for rIX-FP and limited exposure for N9-GP. CONCLUSIONS: The constructed PBPK models provide a mechanistic framework for predicting distinct plasma and tissue-specific distribution profiles for three EHL-FIX concentrates, offering a quantitative basis for exploration of the relationship between extravascular and synovial exposure and bleeding outcomes in haemophilia B.
Autor:innen und Institutionen
- Hospital Pharmacy-Clinical Pharmacology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
- Department of Pharmaceutical Biosciences, Translational Drug Discovery and Development, Uppsala University, Uppsala, Sweden.
- Pharmetheus, Uppsala, Sweden.
- Université Paris-Saclay, Institut National de la Santé et de la Recherce Médicale (Inserm), Hémostase Inflammation Thrombose HITh U1176, 94276, Le Kremlin-Bicêtre, France.
- Department of Pediatric Hematology and Oncology, Erasmus MC Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands.
- Hospital Pharmacy-Clinical Pharmacology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands. r.mathot@amsterdamumc.nl.
Förderung
- SYMPHONY NWO-NWA consortium
Zitieren
APA
Koopman, S. F., Sjögren, E., Lenting, P. J., Cnossen, M. H., Mathôt, R. A. A., & OPTI-CLOT Study Group, SYMPHONY Consortium (2026). Exploration of Extravascular Tissue and Synovial Fluid Distribution of Extended Half-Life Factor IX Concentrates by Physiologically Based Pharmacokinetic Modelling. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-026-01716-3
Vancouver
Koopman SF, Sjögren E, Lenting PJ, Cnossen MH, Mathôt RAA, OPTI-CLOT Study Group, SYMPHONY Consortium. Exploration of Extravascular Tissue and Synovial Fluid Distribution of Extended Half-Life Factor IX Concentrates by Physiologically Based Pharmacokinetic Modelling. Clinical Pharmacokinetics. 2026. doi:10.1007/s40262-026-01716-3
BibTeX
@article{Koopman2026,
author = {Koopman, Sjoerd F and Sjögren, Erik and Lenting, Peter J and Cnossen, Marjon H and Mathôt, Ron A A and OPTI-CLOT Study Group, SYMPHONY Consortium, OPTI-CLOT Study Group, SYMPHONY Consortium},
title = {Exploration of Extravascular Tissue and Synovial Fluid Distribution of Extended Half-Life Factor IX Concentrates by Physiologically Based Pharmacokinetic Modelling},
journal = {Clinical Pharmacokinetics},
year = {2026},
doi = {10.1007/s40262-026-01716-3}
}
EUVIMED